NEW YORK, Oct. 25 – Pfizer licensed Valentis’ GeneSwitch gene regulation technology, the companies announced on Wednesday.
The license is non-exclusive for research-use only.
Financial details of the agreement were not disclosed.
Burlingame, Calif.-based Valentis’ GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, according to the company.
In August, Lexicon Genetics licensed Valentis’ GeneSwitch system for use in its functional genomics research.